Rheumatoid Arthritis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Using neutralizing antibodies to tumor necrosis factor (TNF)-alpha we demonstrated that GM-CSF production in RA synovial cell cultures is dependent on the continued presence of active TNF-alpha.
|
1915559 |
1991 |
Rheumatoid Arthritis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Polymorphisms in several genes were associated with IL-6 levels (including IL10, TYK2, and CD40L in SLE and DRB1, NOD2, and CSF1 in RA) or with TNFα levels (including TNFSF4 and CSF2 in SLE and PTPN2, DRB1, and NOD2 in RA).
|
25652333 |
2015 |
Rheumatoid Arthritis
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this study, synovial fibroblasts of a patient from rheumatoid arthritis (RA) were transformed with LT gene to analyze the effect of SV40-mediated transformation on the production of cytokines, such as IL-6, IL-8, and GM-CSF, that are under the control of interleukin-1 beta (IL-1 beta), a physiological inducer of nuclear factor kappa B (NF-kappa B).
|
10470256 |
1999 |
Rheumatoid Arthritis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Rheumatoid synovial endothelial cells produce macrophage colony-stimulating factor leading to osteoclastogenesis in rheumatoid arthritis.
|
17062647 |
2007 |
Rheumatoid Arthritis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial.
|
30999929 |
2019 |
Rheumatoid Arthritis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Moreover, this combination suppressed more IFN-γ secretion and NFAT-regulated gene (GM-CSF and IFN-γ) expression in RA-MNCs than normal MNCs via decreasing the activity of NFATc1.
|
22385242 |
2012 |
Rheumatoid Arthritis
|
0.400 |
Biomarker
|
disease |
BEFREE |
We have reported previously that metastatic lymph node 51 (MLN51) and granulocyte-macrophage colony-stimulating factor (GM-CSF) are involved in the proliferation of fibroblast-like synoviocytes in the pathogenesis of rheumatoid arthritis.
|
18513326 |
2008 |
Rheumatoid Arthritis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In contrast, GM-CSF in SFs existed at a significant level in the patients with RA (n = 6), in comparison with the other inflammatory cytokines, IL-1beta and TNF-alpha.
|
17101062 |
2006 |
Rheumatoid Arthritis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Constitutive mRNA and protein production of macrophage colony-stimulating factor but not of other cytokines by synovial fibroblasts from rheumatoid arthritis and osteoarthritis patients.
|
8019788 |
1994 |
Rheumatoid Arthritis
|
0.400 |
Biomarker
|
disease |
BEFREE |
IL-13, granulocyte colony stimulating factor (G-CSF), granulocyte macrophage colony stimulating factor (GM-CSF), and TNF-beta mRNAs were found more predominantly in infant samples and in samples from patients with rheumatoid arthritis (RA) compared with samples from patients with osteoarthritis (OA).
|
8853228 |
1996 |
Rheumatoid Arthritis
|
0.400 |
Biomarker
|
disease |
BEFREE |
To determine the molecular basis for the MTX anti-inflammatory action, we explored toll-like receptor (TLR), RA synovial fluid (RASF) and tumour necrosis factor receptor (TNFR)-initiated signalling in MTX-exposed GM-CSF-primed macrophages.
|
29431121 |
2018 |
Rheumatoid Arthritis
|
0.400 |
Biomarker
|
disease |
BEFREE |
CD34+ cells purified from the bone marrow of 13 patients with active RA and 9 control subjects (7 osteoarthritis [OA] patients and 2 healthy individuals) were cultured in the presence of stem cell factor (10 ng/ml) and granulocyte-macrophage colony-stimulating factor (1 ng/ml).
|
15593185 |
2004 |
Rheumatoid Arthritis
|
0.400 |
Biomarker
|
disease |
BEFREE |
We previously proposed the hypothesis that the pro-inflammatory cytokine tumor necrosis factor-alpha (TNF-alpha) plays a pivotal role in the pathogenesis of rheumatoid arthritis (RA) based on our observations that it is the dominant inducer of interleukin-1 (IL-1) and granulocyte-macrophage colony-stimulating factor (GM-CSF) production in RA synovial joint mononuclear (MNC) cells in culture.
|
1320571 |
1992 |
Rheumatoid Arthritis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a pleiotropic, Th17-derived cytokine thought to critically contribute to the pathogenesis of diverse autoimmune diseases, including rheumatoid arthritis and psoriasis.
|
28777803 |
2017 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
High efficiency retroviral-mediated gene transduction into CD34+ cells purified from peripheral blood of breast cancer patients primed with chemotherapy and granulocyte-macrophage colony-stimulating factor.
|
7514449 |
1994 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
ACSL1 Regulates TNFα-Induced GM-CSF Production by Breast Cancer MDA-MB-231 Cells.
|
31581558 |
2019 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Leptomeningeal metastasis (LM) can occur as a late manifestation of breast cancer and has traditionally been diagnosed by CSF cytology; however, cytology suffers from low sensitivity and it is believed that many cases of LM go undiagnosed.
|
29906422 |
2018 |
Malignant neoplasm of breast
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We have previously reported that glucocorticoids markedly increase and anti-glucocorticoids (such as RU-486) block c-fms RNA and protein expression in some breast cancer cell lines, but not in others, and that this increase is the consequence of increased transcription from the first, epithelial cell-specific promoter of the c-fms gene (encoding CSF-1R, macrophage colony-stimulating factor receptor).
|
11891846 |
2002 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Clinical use of a pDNA(Her2/neu/CCL21/GM-CSF) vaccine might be particularly promising in minimal residual Her2/neu+ breast cancer.
|
21997231 |
2012 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
The subsequent release of PGE(2) followed by inhibition of GM-CSF production by cells within the bone microenvironment plays an important part in mediating the effects of breast cancer cells on OCL formation and their resorptive activity.
|
14999770 |
2004 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Constitutive production of macrophage colony-stimulating factor by human ovarian and breast cancer cell lines.
|
2646321 |
1989 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Advantages with prophylactic PEG-rhG-CSF versus rhG-CSF in breast cancer patients receiving multiple cycles of myelosuppressive chemotherapy: an open-label, randomized, multicenter phase III study.
|
29230663 |
2018 |
Malignant neoplasm of breast
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The fms oncogene encodes the macrophage colony-stimulating factor receptor (CSF1R), a transmembrane tyrosine kinase receptor, which is abnormally expressed in breast cancer.
|
14767486 |
2004 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Taken together, these findings strongly suggest that CD44 interaction with p115RhoGEF and ROK plays a pivotal role in promoting Gab-1 phosphorylation leading to Gab-1.PI 3-kinase membrane localization, AKT signaling, and cytokine (M-CSF) production during HA-mediated breast cancer progression.
|
12748184 |
2003 |
Malignant neoplasm of breast
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
VEGFA/C and CSF2 mRNA are overexpressed in HER2 positive breast cancer, with VEGFA and CSF2 also overexpressed in basal breast cancer.
|
26173622 |
2015 |